Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
This article was originally published in The Pink Sheet Daily
Executive Summary
Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.
You may also be interested in...
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
With patents on blockbuster drugs – including Roche/Biogen Idec Inc.'s Rituxan (rituximab), Amgen Inc./Pfizer Inc.'s Enbrel (etanercept) and Roche's Herceptin (trastuzumab) – due to expire in key markets within the next three years, there's a renewed buzz around biosimilars as industry players seek to grab a share of this multi-billion dollar opportunity.
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
With patents on blockbuster drugs – including Roche/Biogen Idec Inc.'s Rituxan (rituximab), Amgen Inc./Pfizer Inc.'s Enbrel (etanercept) and Roche's Herceptin (trastuzumab) – due to expire in key markets within the next three years, there's a renewed buzz around biosimilars as industry players seek to grab a share of this multi-billion dollar opportunity.
Change Of Guard At Quintiles India As Company Continues Aggressive Asia Efforts With Samsung Deal
MUMBAI - Quintiles Transnational Corp.'s India CEO Ferzaan Engineer will step down after serving the multinational contract research organization since its inception in India more than 13 years ago